Form 4: Bionano Genomics Chief Medical Officer Reports Changes in Beneficial Ownership After Stock Split and RSU Vesting

Alka Chaubey, Chief Medical Officer of Bionano Genomics, reports changes in beneficial ownership due to a stock split and the vesting of Restricted Stock Units (RSUs) used to cover tax obligations.

Summary

• On February 19, 2025, Alka Chaubey, the Chief Medical Officer of Bionano Genomics, filed a Form 4 with the SEC.
• The filing reports changes in her beneficial ownership of Bionano Genomics common stock.
• These changes are due to two events: a 1-for-60 stock split that occurred on January 24, 2025, and the vesting of RSUs on February 15, 2025.
• The vesting of RSUs resulted in the withholding of 18 shares to cover tax obligations.
• Following these transactions, Chaubey directly owns 737 shares of Bionano Genomics common stock.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing detailing changes in stock ownership due to a stock split and RSU vesting, which are neutral events.

Industry Context

Form 4 filings are a routine part of insider trading regulations, providing transparency into the transactions of company insiders. Stock splits are corporate actions that can impact share price and liquidity. RSU vesting is a common form of equity compensation.

Stakeholder Impact

• The stock split may affect shareholders by changing the number of shares they own, but it should not affect the overall value of their holdings immediately.
• The RSU vesting impacts the executive's compensation and aligns their interests with the company's performance.

Key Dates

Keywords

Form 4, Beneficial Ownership, Bionano Genomics, BNGO, Stock Split, RSU, Vesting, Tax Withholding, Alka Chaubey, Chief Medical Officer